Efficacy News and Research

RSS

Dietary plant sugar promotes antitumor immunity and enhances the efficacy of immunotherapy

Immunotherapies have improved outcomes of many patients with cancer, including melanoma. But these therapies work for only a subset of patients.

23 Jan 2023

Review on lateral flow test use spearheaded by SARS-CoV-2 pandemic

Researchers assessed the changing landscape of lateral flow tests (LFTs), and the development of next-generation LFTs based on lessons learnt from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.

23 Jan 2023

More high-risk patients with pulmonary embolism may benefit from surgical intervention

A new American Heart Association scientific statement suggests surgery be considered for more people with high-risk pulmonary embolism (PE).

23 Jan 2023

Researchers identify a few factors that can impact the spread of COVID-19

COVID-19 came as an unexpected challenge for humanity. Countries adopted different, sometimes diametrically opposed approaches to minimising the pandemic's impact: from hard lockdowns to no restrictions at all, as in Sweden.

23 Jan 2023

In silico study suggests SARS-CoV-2 Omicron XBB.1.5 strain to be more infective than previous strains

Researchers performed an in silico analysis to estimate the relative risks of recently emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants.

23 Jan 2023

Study shows that SARS-CoV-2 infection is associated with an increased risk for maternal morbidity and severe complications

Researchers examined vaccine effectiveness and pregnancy outcomes during the SARS-CoV-2 Omicron period.

23 Jan 2023

Bivalent BA.4-5 or BA.1 mRNA-booster given as a fourth dose associated with increased protection against COVID-19 hospitalization and death

Researchers compared the efficiency of the SARS-CoV-2 Omicron BA.4-5 and BA.1 bivalent mRNA-booster vaccines.

23 Jan 2023

Potent small-molecule inhibitors against SARS-CoV, MERS-CoV, and SARS-CoV-2

In a recent study posted to bioRxiv* preprint server, researchers in the United States identified several potent pan-coronavirus (CoV) inhibitors.

23 Jan 2023

SARS-CoV-2 Omicron XBB.1.5, CA.3.1, and CH.1.1 exhibit remarkable antibody resistance

In a recent study posted to bioRxiv* preprint server, researchers at Ohio State University examined the degree of neutralizing antibody (nAb) evasion by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron XBB.1.5, CA.3.1, and CH.1.1 subvariants.

23 Jan 2023

Phase I trial results from AdaptVac's COVID capsid virus-like particle vaccine

In a recent study published in The Lancet Microbe journal, researchers described the effectiveness of a modular capsid virus-like coronavirus disease 2019 (COVID-19) vaccination.

22 Jan 2023

Gene editing could offer a promising solution for treating patients after a heart attack

Editing a gene that prompts a cascade of damage after a heart attack appeared to reverse this inevitable course in mice, leaving their hearts remarkably unharmed, a new study by UT Southwestern scientists showed.

20 Jan 2023

People with hybrid immunity are the most protected against severe COVID-19 and reinfection

A University of Calgary research group - which includes several Bachelor of Health Sciences alumni joined forces with members of the World Health Organization to tackle a global health question.

20 Jan 2023

Advantages and challenges of using interstitial fluid for disease diagnosis, health monitoring

The next frontier of continuous health monitoring could be skin deep.

20 Jan 2023

New trial evaluates Omicron BA.1–adapted BNT162b2 vaccine in older adults

Researchers reported the findings of the phase III trial evaluating the Omicron BA.1–adapted mono and bivalent BNT162b2 coronavirus disease 2019 (COVID-19) vaccine in 55-year-old adults. These individuals had already received three 30μg doses of the BNT162b2 vaccine.

20 Jan 2023

WHO to launch council to accelerate the development of TB vaccine

The World Health Organization announces the creation of the TB Vaccine Accelerator Council.

20 Jan 2023

Researchers create the first 'living medicine' to treat drug-resistant lung infections

Researchers have designed the first 'living medicine' to treat lung infections. The treatment targets Pseudomonas aeruginosa, a type of bacteria which is naturally resistant to many types of antibiotics and is a common source of infections in hospitals.

19 Jan 2023

Wistar scientists receive $397,663 to explore the ability of natural killer cells to kill HIV-infected cells

amfAR, The Foundation for AIDS Research, has awarded Luis J. Montaner, D.V.M., D.Phil., in collaboration with Mohamed Abdel-Mohsen, Ph.D., a Target Grant for $397,663 over two years. Montaner, who leads The Wistar Institute's HIV Research Program, is studying the ability of a type of immune cell known as natural killer (NK) cells to kill HIV-infected cells.

19 Jan 2023

Exploring the infectivity, transmissibility, and immunological resistance characteristics of SARS-CoV-2 Omicron XBB.1.5 strain

Researchers performed an epidemic dynamic analysis to assess the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern (VOC)’s sub-VOC XBB.1.5 characteristics.

19 Jan 2023

Researchers find that study results converge on a consistent relationship between antibody levels and protection from COVID-19

Researchers described the factors associated with protection, protection thresholds, and immunobridging in COVID-19 patients.

19 Jan 2023

Study elucidates the potential role of STRO-001 in B-cell non-Hodgkin lymphoma

A new research paper was published in Oncotarget's Volume 14 on January 12, 2023, entitled, "Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001."

18 Jan 2023

Efficacy News and Research

Dietary plant sugar promotes antitumor immunity and enhances the efficacy of immunotherapy

Review on lateral flow test use spearheaded by SARS-CoV-2 pandemic

More high-risk patients with pulmonary embolism may benefit from surgical intervention

Researchers identify a few factors that can impact the spread of COVID-19

In silico study suggests SARS-CoV-2 Omicron XBB.1.5 strain to be more infective than previous strains

Study shows that SARS-CoV-2 infection is associated with an increased risk for maternal morbidity and severe complications

Bivalent BA.4-5 or BA.1 mRNA-booster given as a fourth dose associated with increased protection against COVID-19 hospitalization and death

Potent small-molecule inhibitors against SARS-CoV, MERS-CoV, and SARS-CoV-2

SARS-CoV-2 Omicron XBB.1.5, CA.3.1, and CH.1.1 exhibit remarkable antibody resistance

Phase I trial results from AdaptVac's COVID capsid virus-like particle vaccine

Gene editing could offer a promising solution for treating patients after a heart attack

People with hybrid immunity are the most protected against severe COVID-19 and reinfection

Advantages and challenges of using interstitial fluid for disease diagnosis, health monitoring

New trial evaluates Omicron BA.1–adapted BNT162b2 vaccine in older adults

WHO to launch council to accelerate the development of TB vaccine

Researchers create the first 'living medicine' to treat drug-resistant lung infections

Wistar scientists receive $397,663 to explore the ability of natural killer cells to kill HIV-infected cells

Exploring the infectivity, transmissibility, and immunological resistance characteristics of SARS-CoV-2 Omicron XBB.1.5 strain

Researchers find that study results converge on a consistent relationship between antibody levels and protection from COVID-19

Study elucidates the potential role of STRO-001 in B-cell non-Hodgkin lymphoma

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News